替加环素辅助治疗ICU多重耐药革兰阴性菌感染患者的效果分析  

Analysis of Effect of Tigecycline Adjuvant Therapy in ICU Patients with Multidrug-Resistant Gram-Negative Bacterial Infections

作　　者：谢明娟 Xie Mingjuan(Beijing Aerospace General Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院,北京100076

出　　处：《中国社区医师》2025年第6期27-29,共3页Chinese Community Doctors

摘　　要：目的:探讨替加环素辅助治疗ICU多重耐药革兰阴性菌感染患者的效果。方法:选择2023年1—12月北京航天总医院ICU收治的多重耐药革兰阴性菌感染患者80例作为研究对象,随机分为非辅助组和辅助组,各40例。非辅助组给予头孢哌酮钠舒巴坦钠治疗,辅助组在非辅助组基础上给予替加环素治疗。比较两组康复指标、炎性因子水平、病原菌转阴情况、不良反应发生情况。结果:辅助组ICU治疗时间、呼吸机使用时间、中心静脉置管时间、尿管留置时间短于非辅助组(P<0.05)。治疗2周后,两组C反应蛋白、白细胞计数、降钙素原水平降低,且辅助组低于非辅助组(P<0.05)。辅助组病原菌转阴率高于非辅助组(P=0.016)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:替加环素辅助治疗ICU多重耐药革兰阴性菌感染患者的效果显著,可促进炎症消退,改善患者病情,促进康复,且用药安全性较高。Objective:To explore the effect of tigecycline adjuvant therapy in ICU patients with multidrug-resistant gram-negative bacterial infections.Methods:Eighty patients with multidrug-resistant gram-negative bacterial infections admitted to the ICU of Beijing Aerospace General Hospital from January 2023 to December 2023 were selected as the study subjects.They were randomly divided into a non-adjuvant group and an adjuvant group,with 40 patients in each group.The non-adjuvant group was treated with cefoperazone sodium and sulbactam sodium,while the adjuvant group was treated with tigecycline on the basis of the non-adjuvant group.The rehabilitation indicators,levels of inflammatory factors,negative conversion of pathogenic bacteria and occurrence of adverse reactions were compared between two groups.Results:The ICU treatment time,ventilator usage time,central venous catheterization time and urinary catheterization time in the adjuvant group were shorter than those in the non-adjuvant group(P<0.05).After 2 weeks of treatment,the levels of C-reactive protein,white blood cell count,and procalcitonin in two groups decreased,and the levels in the adjuvant group were lower than those in the non-adjuvant group(P<0.05).The negative conversion rate of pathogenic bacteria in the adjuvant group was higher than that in the non-adjuvant group(P=0.016).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The tigecycline adjuvant therapy is remarkably effective in treatment of ICU patients with multidrug-resistant gram-negative bacterial infections,and can promote inflammation regression,improve patient’s condition,promote recovery,and achieve high medication safety.

关 键 词：多重耐药菌 革兰阴性菌 替加环素 ICU 

分 类 号：R453.2[医药卫生—治疗学]